AstraZeneca’s Camizestrant Clears India’s SEC Review The Story: AstraZeneca’s camizestrant has received a positive SEC recommendation in India for HR-positive, HER2-negative advanced breast cancer wit...
Key Highlights: Implications: Lupin’s launch of Formoflo-G strengthens its respiratory leadership by offering a differentiated triple-combination MDI for COPD. The single-inhaler approach ...
